Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 22993607 | HLA-A*26 | prostate cancer | NA | NA | NA | unclassified | |
| to facilitate the development of a peptide-based cancer vaccine for prostate cancer patients, we examined whether any of the 13 peptides previously reported to induce hla-class i-restricted cytotoxic t lymphocyte (ctl) activity in hla-a3 supertype (-a3, -a11, -a31 and -a33)-positive prostate cancer patients are also capable of inducing ctls restricted to hla-a2, hla-a24 or hla-a26 alleles. | |||||||
| 22993607 | HLA-A*03 | prostate cancer | NA | NA | NA | unclassified | |
| to facilitate the development of a peptide-based cancer vaccine for prostate cancer patients, we examined whether any of the 13 peptides previously reported to induce hla-class i-restricted cytotoxic t lymphocyte (ctl) activity in hla-a3 supertype (-a3, -a11, -a31 and -a33)-positive prostate cancer patients are also capable of inducing ctls restricted to hla-a2, hla-a24 or hla-a26 alleles. | |||||||
| 22993607 | HLA-A*33 | prostate cancer | NA | NA | NA | unclassified | |
| to facilitate the development of a peptide-based cancer vaccine for prostate cancer patients, we examined whether any of the 13 peptides previously reported to induce hla-class i-restricted cytotoxic t lymphocyte (ctl) activity in hla-a3 supertype (-a3, -a11, -a31 and -a33)-positive prostate cancer patients are also capable of inducing ctls restricted to hla-a2, hla-a24 or hla-a26 alleles. | |||||||
| 22993607 | HLA-A*24 | prostate cancer | NA | NA | NA | unclassified | |
| to facilitate the development of a peptide-based cancer vaccine for prostate cancer patients, we examined whether any of the 13 peptides previously reported to induce hla-class i-restricted cytotoxic t lymphocyte (ctl) activity in hla-a3 supertype (-a3, -a11, -a31 and -a33)-positive prostate cancer patients are also capable of inducing ctls restricted to hla-a2, hla-a24 or hla-a26 alleles. | |||||||
| 22993607 | HLA-A*11 | prostate cancer | NA | NA | NA | unclassified | |
| to facilitate the development of a peptide-based cancer vaccine for prostate cancer patients, we examined whether any of the 13 peptides previously reported to induce hla-class i-restricted cytotoxic t lymphocyte (ctl) activity in hla-a3 supertype (-a3, -a11, -a31 and -a33)-positive prostate cancer patients are also capable of inducing ctls restricted to hla-a2, hla-a24 or hla-a26 alleles. | |||||||
| 22993607 | HLA-A*24 | prostate cancer | NA | NA | NA | unclassified | |
| among the 13 peptides tested, a peptide at positions 309 to 318 of b-tubulin 5 exhibited binding activity to the hla-a(*)2402 molecule and induced hla-a24-restricted ctl activity against prostate cancer cells derived from peripheral blood mononuclear cells of prostate cancer patients. | |||||||
| 22993607 | HLA-A*24 | prostate cancer | NA | NA | NA | positive+negation | |
| these results suggest that this peptide could be applicable as a peptide vaccine, not only for hla-a3 supertype-positive, but also for hla-a24-positive prostate cancer patients. | |||||||
| 22993607 | HLA-A*03 | prostate cancer | NA | NA | NA | positive+negation | |
| these results suggest that this peptide could be applicable as a peptide vaccine, not only for hla-a3 supertype-positive, but also for hla-a24-positive prostate cancer patients. | |||||||
| 23233905 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| this included a pilot study of coordinated intraprostatic, autologous dc injection together with radiation therapy with five hla-a2(+) subjects with high-risk, localized prostate cancer; the protocol used androgen suppression, ebrt (25 fractions, 45 gy), dc injections after fractions 5, 15, and 25, and then interstitial radioactive implant. | |||||||
| 23246678 | HLA (HLA) | prostate cancer | NA | NA | NA | negative | |
| as we know, prostate cancer down-regulates expression of hla-1 antigen processing machinery (apm) and has defects in the antigen presentation pathway. | |||||||
Copyright 2024